GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy – FiercePharma
|
GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapy
FiercePharma Despite being one of the most expensive drugs in the world, GlaxoSmithKline’s gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or “bubble boy” syndrome. The drug, which costs … |
Philadelphia Business Journal |
Gilead Drug Approval Fuels Interest in CAR–T Space: 3 Stocks to Consider
Nasdaq Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences’s GILD Yescarta, a cell-based gene therapy, gained approval for the treatment of … 3 Gene Therapy Stocks That Could Make You RichMotley Fool FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasEast Idaho News Kite’s CAR T cell therapy Yescarta gets US FDA nod to treat adults with certain types of large B-cell lymphomapharmabiz.com Pharmaceutical Online (press release) –domain-B –Reuters all 13 news articles » |
|
New Immunotherapy Shows Response for Metastatic Melanoma, Study Says
Curetoday.com A new immunotherapy can slow the progress of metastatic melanoma, according to a small study presented at the 2017 World Congress of Melanoma. The treatment uses tumor infiltrating lymphocytes (TILs) extracted from patients’ tumors, The cells are then … |
|
New Immunotherapy Shows Response for Metastatic Melanoma, Study Says
Curetoday.com A new immunotherapy can slow the progress of metastatic melanoma, according to a small study presented at the 2017 World Congress of Melanoma. The treatment uses tumor infiltrating lymphocytes (TILs) extracted from patients’ tumors, The cells are then … |